Concentrations	3 Months Ended
Mar. 31, 2022
Risks and Uncertainties [Abstract]
Concentrations	8. Concentrations The Company’s revenue is derived primarily from the sale of catheter-based therapeutic devices in the United States. For the three months ended March 31, 2022 and 2021, there were no customers that accounted for more than 10% of the Company’s revenue. As of March 31, 2022 and December 31, 2021, there were no customers that accounted for more than 10% of the Company’s accounts receivable. No vendor accounted for more than 10% of the Company’s purchases for the three months ended March 31, 2022 and 2021. There were no vendors that accounted for more than 10% of the Company’s accounts payable as of March 31, 2022 and December 31, 2021.

The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-URI http://asc.fasb.org/topic&trid=2134479

Name:	us-gaap_ConcentrationRiskDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration